Page 4 - Full Analysis Set News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (SC) administration. REGEN-COV reduced the overall risk of progressing to symptom...

Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance Showed statistically significant onset of action as early as week 2 Had a good safety and tolerability profile throughout the study Topline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescents ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializin...